Novo Nordisk and Eli Lilly presented early research at the ARDD conference suggesting their GLP-1 medications, semaglutide and tirzepatide, may slow molecular biological aging. These findings indicate that the widely used weight-loss and diabetes drugs could offer significant anti-aging benefits beyond their current medical applications.